14 March 2024
14 March 2024
The approval is based on findings from the Phase III MARCH clinical trial in 93 PFIC patients.
Currently authorised for use in adults, the latest EC approval expands the vaccine’s scope to include the pediatric population.
The acquisition will enhance Novartis’ portfolio in inflammation-driven diseases.
The dermatology-centric pharma company is likely set for one of the biggest public listings in Europe since 2022.
This collaboration follows the launch of the Vaccine Development Evaluation Centre (VDEC) by the UKHSA in August last year.
Research puts the spotlight on potential financial conflicts of interest (COI) and limited disclosure practices in pharmaceutical patient-focusing relationships.
The two trials will evaluate alternative dosing regimens for Gardasil 9 vaccine compared to the currently approved three-dose regimen.
With a rising demand for suppositories, the CDMO will bolster production capacity at its facility in Rosenburg, Texas.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
